Newsletter Insights — advertising rates and audience data for 41K+ newsletters
Browse all →
Advertisers are viewing this page. Claim it
Track COVID Intel - by William Makis (McGill Medicine)'s growth
Get notified when subscribers, engagement, or pricing changes
Platform Portability
Uses Substack subdomain (makisw.substack.com). Migrating would require subscribers to re-subscribe at a new address.
Custom domains let newsletters switch platforms without losing their audience.
Are you a newsletter creator? Get verified insights →
Cutting Edge Cancer Research, Repurposed Drugs in Cancer, Ivermectin, Mebendazole, Fenbendazole. Content is for informational purposes only. Entirely donation based. None of the information constitutes medical advice (see your doctor as needed).
Data updated Today
Avg Comments
45.4
Avg Likes
197.5
Engagement Rate
0.16%· ~243 likes + comments/post
(comments + likes) / subscribers
Typical for lists with 149K+ subscribers
Quality Score
Engagement vs Health
0.16% engagement rate
Score Breakdown
Engagement Score
| Public |
| IVERMECTIN and FENBENDAZOLE Testimonial - 59 year old California man with Stage 4 Lung Cancer metastatic to brain reports after 7 monthsOct 14, 2026 | Subscriber-only |
| VIDEO - Oncologists lie about everythingVIDEO - Oncologists lie about everythingOct 13, 2026 | Public |
| IVERMECTIN, MEBENDAZOLE and FENBENDAZOLE Testimonial - 73 year old woman in Israel with Stage 4 Breast Cancer TNBC has almost complete resolution after 7 months!Oct 13, 2026 | Subscriber-only |
| NEWS: The Julie Powell story - 49 year old author wished death on the unvaccinated. Then she died suddenly.I remember reporting Julie Powell’s “sudden death”.Oct 13, 2026 | Public |
| Fraudulent “Unvaccinated COVID deaths” Charts - this never happened. These 2021 "COVID Deaths" charts are 100% fraudulent.Oct 12, 2026 | Public |
| IVERMECTIN, FENBENDAZOLE Testimonial - 61 year old Florida man with Invasive Bladder Cancer reports after 6 monthsOct 11, 2026 | Subscriber-only |
| IVERMECTIN, FENBENDAZOLE Testimonial - 66 year old Ontario man with Stage 4 Prostate Cancer reports after 10 monthsOct 10, 2026 | Subscriber-only |
| IVERMECTIN, FENBENDAZOLE, MCP, CBD Testimonial - 63 year old Canadian woman with Stage 4 Lung Cancer reports after 17 monthsOct 9, 2026 | Subscriber-only |
| IVERMECTIN, FENBENDAZOLE and MEBENDAZOLE Testimonial - 49 year old Texas man with Stage 4 Colon Cancer reports after 9 monthsOct 8, 2026 | Subscriber-only |
vs 138 newsletters in Health
149K places you in the top 10% of newsletters in this category.
Posts per Week
12.7
median: 1.0
Publishing Consistency
96/100
median: 69/100
Subscribers
149K
median: 1K
8.9K paid
Weekly Growth
Stable
Paid Subscriber Retention
+1.4%
net growth
Track revenue changes over time
Start tracking — freeTrack CPM rates as they change
Start tracking — freeSubscriber counts are rounded by the platform — step changes may not reflect actual growth
Publishing Frequency
Daily
Last published Oct 14, 2026
12.7 posts/week avg
Health Pricing
$5/mo median
Above average(+50%)
Monetization Readiness
Already monetizing
92% of similar-size Health newsletters also have paid tiers
Unlock revenue estimates, CPM benchmarks, and detected sponsors
Start tracking — freePriced at $8/mo, 50% above the Health median of $5/mo.
Consistent Publisher
Publishing consistency (96/100) is well above the Health median (69/100).

🌻 A Year of Mental Health
58K subs
Brain Health Kitchen
44K subs
Dr. Michael Okun on Parkinson's & Brain Health
11K subs
Get email alerts when subscribers drop or spike, when new sponsors appear, when pricing changes, or when publishing cadence shifts. Track unlimited newsletters across your watchlist with the Starter plan.
$29/mo·cancel anytime
See what's includedGet the full whitespace list with each brand's category fit, audience overlap, and recommended pitch order. Plus a comparison of COVID Intel - by William Makis (McGill Medicine) vs the top 15 peer newsletters on sponsor mix, growth, and CPM.
Including Pathways, Haxan Ferments, Doordash + 116 more.
$300·2-3 working days·refunded if we can't deliver